People: Inovio Pharmaceuticals Inc (INO.A)

Summary

Name	Age	Since	Current Position
Avtar Dhillon	52	2011	Non-Executive Chairman of the Board
J. Joseph Kim	43	2009	President, Chief Executive Officer, Director
Peter Kies	48	2002	Chief Financial Officer
Niranjan Sardesai	44	2012	Chief Operating Officer
Mark Bagarazzi	51	2010	Chief Medical Officer
Angel Cabrera	45	2012	Director
Simon Benito	67	2003	Independent Director
Morton Collins	76	2009	Independent Director
Adel Mahmoud	71	2012	Independent Director

» Insider Trading

Biographies

Name	Description
Avtar Dhillon	Dr. Avtar S. Dhillon, M.D., is Non-Executive Chairman of the Board of Inovio Pharmaceuticals, Inc. He joined Company as President and Chief Executive Officer, and as a director, in October 2001, served as Chairman and President from June 1, 2009 to October 6, 2009, and served as Executive Chairman until August 1, 2011. Effective August 1, 2011, Dr. Dhillon became Non-Executive Chairman, transitioning from Executive Chairman. Prior to joining, Dr. Dhillon was engaged by MDS Capital Corp. (now Lumira Capital Corp.), one of North America’s healthcare venture capital organizations, as a consultant in July 1998, and subsequently became Investment Manager in August 1999 and Vice President in 2000. In July 1989, Dr. Dhillon started a medical clinic and subsequently practiced family medicine for over 12 years. From March 1997 to July 1998, Dr. Dhillon served as consultant to Cardiome Pharmaceuticals, a biotechnology company listed on NASDAQ National Market and the Toronto Stock Exchange. Dr. Dhillon has a Bachelor of Science, honors degree in physiology and M.D. degree from the University of British Columbia. Dr. Dhillon is also the Chairman of Stevia First Corporation, a publicly traded early stage agri-bio business, and a director of Auricle Biomedical, a capital pool company. Dr. Dhillon has also served since March 2011 as the Non-Executive Chairman of OncoSec Medical, Inc.
J. Joseph Kim	Dr. J. Joseph Kim, Ph.D., is President, Chief Executive Officer, Director of Inovio Pharmaceuticals Inc. He joined Company as Chief Executive Officer and a director on June 1, 2009 and also became President on October 6, 2009. Dr. Kim is a principal architect of SynCon® vaccine technology platform and his leadership is central to business of discovering, developing, and delivering DNA vaccines. He was co-founder of VGX Pharmaceuticals, Inc., or VGX, and its former President, Chief Executive Officer and a director from 2000 to June 2009. Prior to joining VGX, Dr. Kim led efforts in manufacturing and process development of several FDA-approved products and developmental therapeutics at Merck. These products include FDA-approved vaccines for Hepatitis as well as developmental vaccines and therapeutics for HIV/AIDS. Dr. Kim has published over 100 peer-reviewed scientific papers and book chapters, holds numerous patents and sits on several editorial boards and review panels. In 2002, Dr. Kim was named as one of the world’s top 100 young innovators by Technology Review magazine and as one of the “40 under 40” by the Philadelphia Business Journal, which highlights the most dynamic professionals who are under 40 years of age in the region. In 2004, Dr. Kim and VGX were selected as one of 30 Technology Pioneers by the World Economic Forum. Furthermore, Dr. Kim was featured in the “Who’s Next 2005” issue of Newsweek International, which included a group of 10 leaders, scientists, and executives at the forefront of change and impact in the world. Dr. Kim has also been featured in articles in Forbes and the New Yorker and in numerous other Media Outlets. Dr. Kim was trained in economics, engineering and biological sciences at MIT where he was a U.S. Senate Honors Scholar. He holds a Ph.D. in Biochemical Engineering from the University of Pennsylvania and an MBA in Finance from the Wharton School.
Peter Kies	Mr. Peter D. Kies is Chief Financial Officer of Inovio Pharmaceuticals Inc., since June 2002. For the 15 years prior to joining Company, Mr. Kies acquired broad in the functional and strategic management of biotechnology and high technology companies across the full spectrum of corporate growth, from initial public offering to profitability. From May 1996 until joining, he served as Chief Financial Officer for Newgen Results Corporation, and prior to that served as Controller for Cytel Corporation and as an auditor for Ernst & Young LLP. Mr. Kies holds a B.S. in Business Administration from United States International University in San Diego, California.
Niranjan Sardesai	Dr. Niranjan Y. Sardesai, Ph.D., is Chief Operating Officer of Inovio Pharmaceuticals, Inc., effective January 4, 2012. Dr. Sardesai joined VGX Pharmaceuticals as VP Research and Development in 2006, was promoted to SVP R&D in 2007 and, with the merger of VGX with Inovio in June 2009, became SVP Research & Development of the merged company. In January 2012, Dr. Sardesai was named Chief Operating Officer. In his expanded role, Dr. Sardesai is responsible for Corporate Development and Business Development for the company as well as the company’s product development programs in infectious disease and cancer vaccines and vaccine delivery systems. He currently serves as the PI on an NIAID/NIH funded contract for the development of HIV vaccines and an MVI funded program for malaria vaccine development. Prior to VGX, Dr. Sardesai was the founder and President of NVision Consulting Inc., a strategy consulting firm focused on entrepreneurial life sciences companies, and he served as Director R&D at Fujirebio Diagnostics, Inc. At Fujirebio, Dr. Sardesai oversaw R&D and expansion of the oncology portfolio. Products developed under his leadership include new-to-the-world tests for mesothelioma (MESOMARK™), bladder cancer and a multi-marker test for ovarian cancer. He has authored over 40 peer-reviewed publications, presented at over 75 invited lectures and presentations, and filed several patents. Dr. Sardesai received a Ph.D. in Chemistry from the California Institute of Technology and an MBA from the Wharton School of the University of Pennsylvania, where he was the recipient of the Shils-Zeidman Award in Entrepreneurship. He completed fellowships at Scripps Research Institute and Massachusetts Institute of Technology. Dr. Sardesai received his bachelors and masters in Chemistry from the Indian Institute of Technology, Bombay.
Mark Bagarazzi	Dr. Mark L. Bagarazzi, M.D., is Chief Medical Officer of Inovio Pharmaceuticals Inc., January 5, 2010. Prior to joining Inovio, Dr. Bagarazzi was Director of Worldwide Regulatory Affairs for vaccines and biologics at Merck & Co. Dr. Bagarazzi led ongoing vaccine product and regulatory development of Merck’s ZOSTAVAX®, the vaccine for shingles. He was responsible for global regulatory activities related to Merck vaccine candidates for the prevention of HIV/AIDS. He also led the regulatory process through to FDA approval of RotaTeq®, Merck’s vaccine against rotavirus. Prior to joining Merck in 2001, he was director of the HIV/AIDS program for St. Christopher’s Hospital for Children in Philadelphia. Dr. Bagarazzi was an assistant professor of pediatrics at Drexel College of Medicine and is a guest lecturer on vaccines and immunotherapeutics at the University of Pennsylvania School of Medicine. Previously, he was a guest lecturer at Johns Hopkins University. He holds several patents and has co-authored dozens of scientific papers, focused on the subject of DNA vaccines, that have been published in peer-reviewed medical journals. He holds a BS in electrical engineering magna cum laude from New Jersey Institute of Technology and received his MD degree with honors from the University of Medicine and Dentistry of New Jersey.
Angel Cabrera	Dr. Angel Cabrera, Ph.D., has been appointed as Director of Inovio Pharmaceuticals, Inc., effective June 15, 2012. Dr. Cabrera is outgoing president of the Thunderbird School of Global Management, regarded as the world's graduate school of international business. On July 1, Dr. Cabrera will become president of George Mason University, the university in Virginia. During his eight-year term, Dr. Cabrera led a academic, operational and financial overhaul of the international business school, stemming operating deficits and declining revenues and consolidating Thunderbird's leadership position in the global business educational arena. Prior to Thunderbird, Cabrera served as Dean of IE Business School in Madrid, which he helped propel into the top tier of international business schools. Prior to IE he was a change management consultant with Accenture. Angel Cabrera earned his Ph.D. and M.S. in psychology and cognitive science from the Georgia Institute of Technology which he attended as a Fulbright Scholar and his B.S. and M.S. in computer and electrical engineering from Madrid's Polytechnic University, Spain's premier engineering school. He received additional training in cognitive science at Carnegie Mellon University and in global leadership at the Harvard Kennedy School. He has published in fields ranging from learning technology to psychology, management and higher education. His most recent book, "Being Global: How to Think, Act and Lead in a Transformed World," was recently published by Harvard Business Review Press. Dr. Cabrera is an advocate of corporate social responsibility and managerial professionalism.
Simon Benito	Mr. Simon X. Benito is Independent Director of Inovio Pharmaceuticals Inc., since December 18, 2003. Prior to his retirement, Mr. Benito had a career serving several health care companies in senior executive positions, including 25 years at Merck & Co, Inc. His most recent positions included Senior Vice President, Merck Vaccine Division; Executive Vice President, Merck-Medco Managed Care; and Executive Director and Vice President, Merck Human Health, Japan. In addition, Mr. Benito was a Fellow of the Institute of Chartered Accountants in England and Wales for over 30 years until his retirement in 1999. Since April 2005, Mr. Benito has served as a director of DURECT Corporation, a publicly traded specialty pharmaceutical company.
Morton Collins	Dr. Morton Collins, Ph.D., is Independent Director of Inovio Pharmaceuticals Inc., since June 1, 2009. Dr. Collins was previously a director of VGX from June 2008 to June 2009. Dr. Collins has been a General Partner of Cardinal Partners since July 2003 and Innovation Valley Partners since August 2005. For the past 40 years, Dr. Collins has acquired broad in venture capital funding of early-stage high-technology companies as a founder and managing partner of five different funds, Data Science Ventures I, II, III, and IV and Cardinal Partners. He chaired President Reagan’s Task Force on Innovation and Entrepreneurship and served as a technology policy advisor to President George H. W. Bush. He is a former President, Director and Chairman of the National Venture Capital Association, and currently serves as Director to Kopin Corporation and several private companies. Dr. Collins holds a B.S. in Engineering from the University of Delaware, and his M.A. and Doctorate degrees in Engineering from Princeton University.
Adel Mahmoud	Dr. Adel A. F. Mahmoud, M.D., Ph.D., is Independent Director of Inovio Pharmaceuticals Inc., effective March 26, 2012. Dr. Mahmoud is at The Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University. He has recently retired as President of Merck Vaccines and member of Management Committee of Merck & Company, Inc. His prior academic services at Case Western Reserve University and University Hospitals of Cleveland spanned 25 years concluding as Chairman of Medicine and Physician-in-Chief from 1987 to 1998. Dr. Mahmoud’s academic pursuits focused on investigations of the biology and function of eosinophils particularly in host resistance to helminthic infections as well as determinants of infection and disease in human schistosomiasis and other infectious agents. At Merck, Dr. Mahmoud led the effort to develop four new vaccines which have been launched in 2005-2006, including: combination of Measles, Mumps, Rubella and Varicella; Rota Virus; Shingles and Human Papillomavirus. Dr. Mahmoud’s leadership in setting strategies for Global Health shaped the agenda of the Forum on Microbial Threats of the Institute of Medicine in recent years by tackling topical issues such as biological threats and bioterrorism; SARS; Pandemic Flu and others. He is an active contributor to scientific literature and authored and edited several textbooks and reports. Dr. Mahmoud received his M.D. degree from the University of Cairo in 1963 and Ph.D from the University of London, School of Hygiene and Tropical Medicine in 1971. He was elected to membership of the American Society for Clinical Investigation in 1978, the Association of American Physicians in 1980 and the Institute of Medicine of the National Academy of Sciences in 1987. He received the Bailey K. Ashford Award of the American Society of Tropical Medicine and Hygiene in 1983, and the Squibb Award of the Infectious Diseases Society of America in 1984.

Basic Compensation

Name	Fiscal Year Total
Avtar Dhillon	657,202
J. Joseph Kim	903,597
Peter Kies	453,440
Niranjan Sardesai	459,760
Mark Bagarazzi	444,965
Angel Cabrera	--
Simon Benito	--
Morton Collins	--
Adel Mahmoud	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Avtar Dhillon	718,746	163,748
J. Joseph Kim	0	0
Peter Kies	91,875	34,025
Niranjan Sardesai	0	0
Mark Bagarazzi	0	0
Angel Cabrera	0	0
Simon Benito	0	0
Morton Collins	0	0
Adel Mahmoud	0	0

Insider Trading

Name	Shares Traded	Price
BAGARAZZI MARK L	60,000	$0.56
KIM JONG JOSEPH	90,000	$0.50
CABRERA ANGEL	40,000	$0.54
SARDESAI NIRANJAN Y	25,000	$0.53
KIM JONG JOSEPH	60,000	$0.53
COLLINS MORTON	50,000	$0.67
COLLINS MORTON	50,000	$0.67
KIM JONG JOSEPH	50,000	$0.53
KIM JONG JOSEPH	50,000	$0.53
KIM JONG JOSEPH	150,000	$0.53
KIM JONG JOSEPH	50,000	$0.53
AUSTIN W MARXE ET AL	25,000	$0.55
AUSTIN W MARXE ET AL	92,800	$0.55
AUSTIN W MARXE ET AL	250,000	$0.55
AUSTIN W MARXE ET AL	168,700	$0.54
AUSTIN W MARXE ET AL	96,000	$0.57
AUSTIN W MARXE ET AL	650,000	$0.49
AUSTIN W MARXE ET AL	300,000	$0.47
AUSTIN W MARXE ET AL	123,900	$0.47
AUSTIN W MARXE ET AL	230,000	$0.47
AUSTIN W MARXE ET AL	126,800	$0.47
AUSTIN W MARXE ET AL	220,099	$0.48
AUSTIN W MARXE ET AL	500,000	$0.48
AUSTIN W MARXE ET AL	500,000	$0.46
AUSTIN W MARXE ET AL	400,000	$0.52

» Full list on Insider Trading

People: Inovio Pharmaceuticals Inc (INO.A)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: